ImmunoForge to Host Strategic Partnering Meetings During J.P. Morgan Healthcare Conference 2026
— Focusing on global out-licensing of Phase 2 assets PF1801 and PF1804. — Company to engage with global big pharma in San Francisco to accelerate U.S. clinical entry. ImmunoForge Co., Ltd. (Co-CEOs Sung-Min Ahn and Kiho Chang), a clinical-stage biopharmaceutical company specializing in rare diseases, today announced that its leadership team will be in San […]